CD3/CD19 BiTE® - Mechanism of Action
The CD3/CD19 BiTE® is a biopharmaceutical drug known as a Bi-specific T-cell engager for a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to cancer cells expressing specific cancer antigens (e.g. CD19). The binding event potentiates unstimulated T-cells and induces direct cytotoxicity against CD19+ cancer cells.
BPS has demonstrated the capability of assessing the functional activities of a commercially available CD3/CD19 BiTE® using our reporter cell lines, Jurkat/NFAT-luc or Jurkat/IL2-Luc.
Experimental Procedures
First, Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-Luc or IL-2 promoter-Luc cells are incubated with increasing concentrations of the CD3/CD19 BiTE®in the presence or absence of CD19+ Raji cells. Secondly, the CD3/CD19 BiTE® simultaneously binds to TCR/CD3 on the Jurkat reporter cells and tumor antigen CD19 on the target Raji cells. Finally, its binding stimulates NFAT or IL-2 luciferase activity and the luciferase activity is assessed by our ONE-Step™ Luciferase Assay System.
BsAb-related Services
BPS offers customized services for generating BiTE® constructs and producing BiTE® antibodies, measuring the affinity for BiTE® antibody binding to antigen using interferometry (Gator™, Probe Life) or ELISA-based assay, and assessing T cell activation using reporter cell-based assays. BPS also offers over 200 cell lines expressing antigens on cancer cells on CHO or HEK293 cells, including our CD19-CHO Cell Line and several reporter cell lines including NFAT(Luc)/Jurkat cell lines for BiTE® construct evaluation in a reporter cell-based assay.
If you have further questions or would like to request a quote, please feel free to contact us.
References
您的位置：
立即咨詢
聯系電話：
